Chimerix
Chimerix, Inc. was a biopharmaceutical company headquartered in Durham, North Carolina, focused on developing medicines for serious and life-threatening diseases. It is best known for brincidofovir (TEMBEXA), an antiviral approved by the U.S. FDA in 2021 as a smallpox medical countermeasure, and for dordaviprone (ONC201), an investigational small-molecule therapy for H3 K27M-mutant diffuse glioma, a form of brain cancer. Chimerix was a publicly traded company (NASDAQ: CMRX) and was acquired by Jazz Pharmaceuticals in 2025, primarily for dordaviprone; the chimerix.com domain now redirects to jazzpharma.com. As a clinical-stage pharmaceutical company, Chimerix does not operate a public developer program or API surface — this profile tracks it as a company entity within the API Evangelist network.
Chimerix is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Pharmaceuticals, Oncology, and Antivirals.
Kin Score
Markets this provider is in provisional
The Kin Score Market layer reads a provider inside its market: its position, and how deep its integrations go. Depth is only comparable within a position. Provisional and unweighted: not part of the Kin Score or agent readiness.
| Market | Position | Depth | Registered MCP server | Declares compatibility |
|---|---|---|---|---|
| Clinical Trial Sponsors (drug pipelines) | standard | 56.0 | - | - |
Registered MCP server and declares compatibility are report only — not weighted. Undeclared means we found nothing we can read, so there is no number: we never infer integrations.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Company 1
The organization behind the API
Other 1
Properties that don't map to a standard resource type
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.